Verve Therapeutics appoints Troy Lister as CSO; Andrew Bellinger to resign effective June 21, 2024

Verve Therapeutics, Inc.

Troy Lister, Ph.D., appointed Chief Scientific Officer effective June 21, 2024, succeeding Andrew Bellinger.
Andrew Bellinger resigns as CSO on June 21, 2024; will provide advisory services under an Advisor Agreement.
Bellinger receives 12 months base salary continuation, a $153,765 bonus (67% of target), and limited equity vesting.
Advisor Agreement pays Bellinger $200/hour; cannot be terminated for convenience before two-year anniversary.
Bellinger subject to non-compete for one year after advisor termination; non-disclosure obligations continue.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Andrew Bellinger

Chief Scientific Officer

Verve Therapeutics, Inc.

Effective: 2024-06-21
Successor: Troy Lister
Filed: May 31, 2024, 7:59 PM ET

Andrew Bellinger, M.D., Ph.D., who will resign as the Company's Chief Scientific Officer on the Effective Date.

Appointed

Troy Lister

Chief Scientific Officer

Verve Therapeutics, Inc.

Effective: 2024-06-21
Filed: May 31, 2024, 7:59 PM ET

appointed Troy Lister, Ph.D., as Chief Scientific Officer of the Company, effective June 21, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Bellinger resigned as Chief Scientific Officer at Verve Therapeutics, Inc..

Action: resigned
Role: Chief Scientific Officer

Exact text from the filing

Andrew Bellinger, M.D., Ph.D., who will resign as the Company's Chief Scientific Officer on the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Troy Lister was appointed as Chief Scientific Officer at Verve Therapeutics, Inc..

Action: appointed
Role: Chief Scientific Officer

Exact text from the filing

appointed Troy Lister, Ph.D., as Chief Scientific Officer of the Company, effective June 21, 2024

View on SEC.gov

Source: SEC EDGAR

accession 0001193125-24-151009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.